Risk of motor vehicle collisions after methadone use
- Department of Health-Business Administration, Fooyin University, Taiwan
- Division of Medical Statistics and Bioinformatics, Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Taiwan
- Department of Oral Hygiene, College of Dental Medicine, Kaohsiung Medical University, Taiwan
- Department of Healthcare Administration, Asia University, Taiwan
- Department of Psychiatry, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Taiwan
- Department of Computer Science and Engineering, National Sun Yat-sen University, Taiwan
- Department of Psychiatry, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taiwan
- Ph.D. Program in Environmental and Occupation Medicine, (Taiwan) National Health Research Institutes and Kaohsiung Medical University, Taiwan
- Tzu Chi University, Taiwan
- Environmental and Occupational Medicine, National Taiwan University College of Medicine and NTU Hospital, Taiwan
- Department of Environmental and Occupational Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Taiwan
- Department of Public Health, Kaohsiung Medical University, Taiwan
Abstract
Methadone maintenance treatment (MMT) can alleviate opioid dependence. However, MMT possibly increases the risk of motor vehicle collisions. The current study investigated preliminary estimation of motor vehicle collision incidence rates. Furthermore, in this population-based retrospective cohort study with frequency-matched controls, opiate adults receiving MMT (cases) and those not receiving MMT (controls) were identified at a 1:2 ratio by linking data from several nationwide administrative registry databases. From 2009 to 2016, the crude incidence rate of motor vehicle collisions was the lowest in the general adult population, followed by that in opiate adults, and it was the highest in adults receiving MMT. The incidence rates of motor vehicle collisions were significantly higher in opiate users receiving MMT than in those not receiving MMT. Kaplan–Meier curves of the incidence of motor vehicle collisions differed significantly between groups, with a significant increased risk during the first 90 days of follow-up. In conclusion, drivers receiving MMT have higher motor vehicle collision risk than those not receiving MMT in opiate users, and it is worthy of noticing road safety in such drivers, particularly during the first 90 days of MMT.
eLife digest
In 2019, 58 million people were estimated to use opioids – a group of substances that include drugs like heroin and morphine. Dependence on opioids can be managed using a prescribed dose of an opioid called methadone, which is administered through a controlled treatment plan. This so-called methadone maintenance treatment manages withdrawal symptoms in opioid-dependent individuals and can reduce the occurrences of overdose, criminal activity and transmission of diseases such as HIV.
However, methadone acts on the same brain receptors as other opioids, and individuals receiving methadone may experience impaired motoric and cognitive functioning, including reduced driving ability. It is therefore important to know whether methadone maintenance treatment may increase an individual’s risk to cause road accidents.
To assess motor vehicle collision risk associated with individuals receiving methadone maintenance treatment, Yang et al. analysed data from the Taiwan National Health Insurance Research Database and six Taiwanese administrative registries, including the ministries of health and welfare, interior and justice, and registries in substitution maintenance therapy, road accidents and the National Police Agency.
Initial analyses found that individuals receiving treatment had a higher risk to be involved in car accidents than the general adult population or those without methadone maintenance treatment. Further tests showed that individuals receiving treatment were at three times higher risk of collisions than individuals not receiving treatment, particularly in the first 90 days.
These findings may help individuals undergoing methadone maintenance treatment manage their risk of motor vehicle collisions. Further investigation is needed to reveal the underlying mechanisms of methadone-related impairment of driving ability.
Introduction
Approximately 58 million people worldwide had opioid user in 2019, with 30 million accounting for opiate users (United Nations Office on Drugs and Crime, 2020). Iatrogenic opioid dependence has become an epidemic in many developed countries, particularly the United States (Anderson, 2017); in other countries, the number of people using heroin is steadily increasing (United Nations Office on Drugs and Crime, 2018). Opioid dependence clearly presents a public health challenge worldwide. Methadone maintenance treatment (MMT) is a primary medication-assisted treatment for opioid dependence (United Nations Office on Drugs and Crime, 2020; Darke et al., 2006; Hall et al., 2000; Kleber, 2008). MMT can reduce opioid and heroin dependence, opioid overdose incidence, criminal activity, all-cause mortality, and HIV and hepatitis C virus transmission (Degenhardt et al., 2011; Mathers et al., 2010; Hickman et al., 2018; Kamarulzaman et al., 2016; Chen et al., 2012).
Methadone, a full µ-opioid receptor agonist, can alleviate opioid dependence, both (methadone and opioid) of which can influence psychomotor performance and cognitive functioning in healthy volunteers (Zacny, 1995; Zacny, 1996; Rothenberg et al., 1977; Rothenberg et al., 1980; Rothenberg et al., 1980). Hence, older research described little or no difference in cognitive functioning between MMT patients and healthy controls (Gordon, 1970; Gritz et al., 1975; Appel and Gordon, 1976; Grevert et al., 1977; Appel, 1982; Robinson and Moskowitz, 1985).Given such trends, it is likely that when compared with a higher dose of methadone, MMT patients using a stable dose non-significantly impaired (Moskowitz and Robinson, 1985; Kelley et al., 1978). On the contrary, increasing recent evidence has supported that MMT patients using a stable dose may be impaired on a broad set of neuropsychological tests that related to psychomotor speed, decision-making, working memory, and meta-memory (Mintzer and Stitzer, 2002), information processing, attention, short-term verbal and visual memory, long-term verbal memory and problem-solving (Darke et al., 2000) and cognitive functioning (Mintzer et al., 2005; Verdejo et al., 2005; Prosser et al., 2006; Rapeli et al., 2007; Soyka et al., 2008; Prosser et al., 2009), decision-making (Rotheram-Fuller et al., 2004; Ersche et al., 2006), and driving aptitude (Schindler et al., 2004; Baewert et al., 2007). However, MMT itself may elevate the motor vehicle collision risk (Bramness et al., 2012; Corsenac et al., 2012; Leveille et al., 1994).
Thus far, few observational epidemiological studies (Bramness et al., 2012; Corsenac et al., 2012; Leveille et al., 1994; Babst et al., 1973; Blomberg and Preusser, 1974; Maddux et al., 1977) have been published on the relationship between motor vehicle collisions and MMT; of these, three were performed in the 1970s and used a case-comparison design to investigate drivers receiving MMT in the United States in small-to-medium-sized cohorts (Babst et al., 1973; Blomberg and Preusser, 1974; Maddux et al., 1977). Their results indicated no significant differences in the rate of motor vehicle collisions between drivers receiving MMT and healthy controls. By contrast, three more recent studies (Bramness et al., 2012; Corsenac et al., 2012; Leveille et al., 1994) found that patients receiving buprenorphine maintenance treatment or MMT had a significantly increased incidence of motor vehicle collisions. Although these studies used medium-to-large-sized cohorts, they neglected some potential risk factors for motor vehicle collisions among drivers receiving MMT, particularly opiate use. Most patients receiving MMT in the aforementioned studies had a history of opioid or heroin dependence. Analgesic opioid users have a 1.8 times higher motor vehicle collision risk than do nonusers (Leveille et al., 1994; Gibson et al., 2009). Similarly, heroin users have higher motor vehicle collision risk than do healthy people (Edwards and Quartaro, 1978). Thus, opiate use history must be identified when estimating motor vehicle collision risks related to MMT use. Few studies have proposed effective measures for motor vehicle collision prevention in drivers receiving MMT.
To investigate whether drivers receiving MMT have an increased motor vehicle collision risk, we analyzed nationwide motor vehicle collision incidence rate in three groups as preliminary data: general adult population, adult opiate users, and adults receiving MMT. Furthermore, by using these data, we created population-based matched retrospective cohorts of new opiate users receiving and not receiving MMT. Moreover, we should provide some suggestions for early prevention of motor vehicle collisions in opiate users receiving MMT.
Methods
Data source
Data were retrieved from the Taiwan National Health Insurance Research Database (NHIRD) (Wu and Lee, 2016; Hu et al., 2019) and six Taiwanese population-based administrative registries, namely the management information system of substitution maintenance therapy, Ministry of Health and Welfare, the road accident registry of injurious crashes, National Police Agency, Ministry of the Interior, and four independent management information systems at the Ministry of Justice, Republic of China (Taiwan). The four information systems were the case management system of Drug Prevention and Control Center, processing system of criminal records, criminal case system of drug case prosecutor briefed the transfer of information, and punitive administrative system for the use of Category 3 or 4 Narcotics (illicit drugs). Preliminary data were independently collected by the aforementioned governmental departments and managed by the Health and Welfare Data Science Center, Ministry of Health and Welfare. Data from different systems were linked using the unique national identification numbers assigned to each citizen in Taiwan. For the consideration of privacy protection, all of the personal identifications were recorded, only authorized researchers were permitted to process databases in a separated designate area, and only statistical results were allowed to be carried out for publications. Personal identifiers were removed after the linkage and before the analysis.
Study population
We combined and organized the four registry databases from the four independent management information systems at the Ministry of Justice (Figure 1). The total number of opiate users in the registry from 1956 to 2016 was 107,213. From the four registry databases, we identified new opiate users between 2010 and 2016 (n = 15,996), who were defined the first detection by law enforcement. The new opiate users were excluded if they (1) were registered at <20 years of age; (2) used opiate before 2010; and (3) had incomplete information on age, sex, education status, income, residing in area, etc. Of the new opiate users, we selected those receiving MMT as the (MMT) exposed group, who were regular methadone users. The date of first MMT administration was defined as the index date. Other new opiate users not receiving MMT were randomly selected as the (MMT) unexposed group after they were frequency-matched to the exposed group at a ratio of 1:2 according to age, sex, and opiate use duration. Thereafter, the index date of two matched unexposed users was the same day as that of the exposed user. The included participants had not been in jail after their index date. Figure 1 depicts the flow of patient selection in the present study. Potential covariates, including history of motor vehicle collisions, driving under the influence (DUI), antidepressant use, and BZD (including Z-drug) use before the index date, were included in the analysis (Bramness et al., 2012; Corsenac et al., 2012; World Health Organization, 2018; Chang et al., 2013; Engeland et al., 2007; World Health Organization, 2004).
Figure 1
Flow chart of participant selection.
Study outcomes and potential covariates
The road accident registry of injurious crashes provided information regarding motor vehicle collisions involving personal death, injury, or vehicle damage on Taiwanese roads; the subjects of the current study were focused on the drivers of the road accidents in the database. The main outcome was the incidence of motor vehicle collisions after the index date. All participants were followed until motor vehicle collision after the index date, death, end of follow-up in registry records, or the end of 2016.
Data regarding methadone treatment were extracted from the 2007–2016 management information system of substitution maintenance therapy, which includes information on all prescriptions issued by at least two psychiatrists in Taiwan. This registry omits drug administration information of individuals who were hospitalized or received medications dispensed by outpatient departments. Methadone is dispensed to individuals who meet the criteria for opioid use (dependence or abuse) as defined by the International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM 304.00–304.03, 304.70–304.83, and 305.50–305.53). Patients receiving MMT must comply with daily witnessed ingestion under the supervision of a pharmacist or psychiatric nurse and are forbidden to take medication away from treatment sites. Methadone dosing and treatment duration are individualized, varying according to patient tolerance and clinical response across treatment stages (induction, titration, and stabilization) according to the Regulations for MMT Guidelines in Taiwan Centers for Disease Control, 2007; Department of Health, Executive Yuan of Taiwan, 2006.
Statistical analyses
All statistical analyses were performed using SAS (version 9.1, SAS Institute, Cary, NC, USA). Participants were stratified on the basis of age, sex, duration of opiate use, education status, income level, urbanity, history of motor vehicle collisions, DUI, antidepressant use, and BZD (Z-drug) use by using the Pearson χ2 test. To determine the independent effect of MMT on motor vehicle collision risk in a previous opiate user, we used a proportional hazard model after adjusting for motor vehicle collisions, as stated previously. The Kaplan–Meier method and log-rank test were used to estimate and compare the incidence of motor vehicle collisions between participants receiving and not receiving MMT, assuming a two-tailed alpha level of statistical significance of 0.05.
Results
Crude incidence rates of motor vehicle collisions
Figure 2 shows the crude incidence rates (CIRs) of motor vehicle collisions in Taiwan during 2009 to 2016 among the general adult population, adult opiate users, and adults receiving MMT. The CIRs of motor vehicle collisions in the general adult population slightly increased from 19.2 per 1000 person-years in 2009 to a peak of 30.6 per 1000 person-years in 2014 but steadily decreased to 30.3 per 1000 person years in 2016. Over the follow-up period, the CIRs of motor vehicle collisions in adultopiate users followed a similar trend––from 28.2 to 46.8 per 1000 person-years. In the general adult population receiving MMT, the highest CIR of motor vehicle collisions was noted in 2012 (58.7 per 1000 person-years), with a wide range of 37.5 to 58.7 per 1000 person-years. Overall, the CIRs of motor vehicle collisions from 2009 to 2016 were the lowest in the general adult population, followed by those in adult opiate users, and they were the highest in adults receiving MMT.
Figure 2
Crude incidence rates (CIRs) of motor vehicle collisions annually among the general adult population, adult opiate users, and patients receiving methadone maintenance treatment (MMT).
The CIRs of motor vehicle collisions in Taiwan during 2009–2016 among the general adult population, adult opiate users, and adults receiving MMT are shown. The CIRs of motor vehicle collisions in the general adult population slightly increased from 19.2 per 1000 person-years in 2009 to a peak of 30.6 per 1000 person-years in 2014 but steadily decreased to 30.3 per 1000 person-years in 2016. Over the follow-up period, the CIRs of motor vehicle collisions in adult opiate users followed a similar trend—from 28.2 to 46.8 per 1000 person-years. In the general adult population receiving MMT, the highest CIR of motor vehicle collisions was noted in 2012 (58.7 per 1000 person-years), with a wide range of 37.5–58.7 per 1000 person-years. Overall, the CIRs of motor vehicle collisions from 2009 to 2016 were the lowest in the general adult population, followed by those in adult opiate users, and they were the highest in adults receiving MMT.
Cohort population characteristics
Data from 3036 opiate users—including 1012 opiate users receiving MMT (MMT group) and 2024 opiate users not receiving MMT (controls)—were included in the 7-year follow-up cohort (median 5.0 years per person; interquartile range 2.9–5.9 years). The baseline characteristics of opiate users are shown in Table 1. The mean age (± standard deviation) at presentation was 37.7 (± 8.1) years. The mean duration of opiate use was 15.3 (± 15.4) months, and 85.6% (n = 2598) of the participants were male. No significant between-group differences were observed in these characteristics, including urbanization of the area of residence and history of motor vehicle collisions and DUI. The participants receiving MMT had a lower education level but higher income than did the controls (both p<0.001). The MMT group had significantly more exposure to antidepressants (8.4 and 5.1%, respectively; p<0.001) and BZD (Z-drugs) (63.5 and 18.2%, respectively; p<0.001) than did the controls.
Table 1
Baseline characteristics of opiate users in Taiwan, 2010–2016.
| Characteristics | MMT n = 1012 | Non-MMT n = 2024 | p | |||
|---|---|---|---|---|---|---|
| Age, mean (SE), years | 37.7 (8.1) | 37.7 (8.1) | 1.000 | |||
| Length of time on opiate users’ registry, mean (SE), months | 15.3 (15.4) | 15.3 (15.4) | 1.000 | |||
| Sex, n (%) | 1.000 | |||||
| Male | 866 | (85.6) | 1732 | (85.6) | ||
| Female | 146 | (14.4) | 292 | (14.4) | ||
| Education status, n (%) | <0.001 | |||||
| Elementary school (1–6 years) | 91 | (9.0) | 115 | (5.7) | ||
| High school (7–12 years) | 896 | (88.5) | 1832 | (90.5) | ||
| College or more (>12 years) | 25 | (2.5) | 77 | (3.8) | ||
| Income level, n (%) | <0.001 | |||||
| ≦15,000 (New Taiwan $) | 615 | (60.8) | 1394 | (68.9) | ||
| Urbanity, n (%) | 0.240 | |||||
| Urban | 701 | (69.3) | 1453 | (71.8) | ||
| Suburban | 27 | (2.7) | 60 | (3.0) | ||
| Rural | 284 | (28.1) | 511 | (25.3) | ||
| Past history of, n (%) | ||||||
| Motor vehicle collision | 339 | (33.5) | 623 | (30.8) | 0.129 | |
| Driving under the influence | 67 | (6.6) | 106 | (5.2) | 0.121 | |
| Antidepressant use | 85 | (8.4) | 104 | (5.1) | <0.001 | |
| Benzodiazepine (Z-drug) use | 643 | (63.5) | 369 | (18.2) | <0.001 | |
| Occurrence of | ||||||
| Motor vehicle collision, n (%) | 66 | (6.5) | 45 | (2.2) | <0.001 | |
| Duration*, mean (SE), days | 234.8 (295.0) | 226.7 (287.7) | 0.886 | |||
-
*Length of time from the index date to motor vehicle collision event after the index date, death, end of follow-up in registry, or the end of 2016.
MMT: methadone maintenance treatment.
Study outcomes and potential covariates
During the study period, the incidence rates of motor vehicle collisions were 6.5 and 2.2% in the MMT group and controls, respectively. The mean time interval from the index date to a motor vehicle collision was similar between the groups (234.8 ± 295.0 and 226.7 ± 287.7 days, respectively; p=0.886; Table 1). Figure 3 shows the Kaplan–Meier analysis for motor vehicle collision-free survival between opiate users receiving MMT and those not receiving in long-term and short-term follow-up. From the survival curve of 7-year follow-up, the upper panel of Figure 3 shows that both MMT and control groups had similar patterns of motor vehicle collision-free survival. From the further analysis during 100-day follow-up, it began to have no differences between both groups in the first 30 days of MMT intervention, but, after the first 30 days, differences were noted. Notably, a rapid descending curve in the MMT group was discovered in the first 90 days; later, the curve descended steadily. Overall, descending rate of motor vehicle collision-free survival in the MMT group (6.5%; range 5.23–7.08%; 95% confidence interval [95% CI], 5.23–7.08) was significantly higher than that in the control group (2.2%; range 1.90–2.41%; log-rank test p<0.001) (Figure 3).
Figure 3
The Kaplan–Meier curve of motor vehicle collision-free between opiate users receiving methadone maintenance treatment and those not receiving in long-term (7 years, upper panel) and short-term (100 days, lower panel) follow-up.
Univariate analysis results indicated that compared with the controls, opiate users receiving MMT had an increased risk of motor vehicle collisions (crude hazard ratio [HR] 3.00 [95% CI, 2.05–4.38]; log-rank test p<0.001). The risk of motor vehicle collisions was the highest in participants with a history of DUI (crude HR 2.26 [95% CI, 1.26–4.01]; p=0.006), followed by that in those with antidepressant exposure (crude HR 2.25 [95% CI, 1.26–3.93]; p=0.005). Factors predictive of motor vehicle collisions were history of motor vehicle collisions (crude HR 1.70 [95% CR, 1.17–2.48]; p=0.006), BZD (Z-drug) use (crude HR 1.62 [95% CI, 1.09–2.42]; p=0.018), and rural location (crude HR 1.68 [95% CI, 1.14–2.46]; p=0.009; Table 2). Multivariate analysis showed that after adjustments for income level, urbanity, education status, history of motor vehicle collisions, DUI, BZD (Z-drug) use, and antidepressant use, the adjusted HR for motor vehicle collisions in the MMT group was 2.75 (95% HR, 1.87–4.04; p<0.001), indicating that opiate users receiving MMT had a significantly increased motor vehicle collision risk. In addition, participants residing in urban areas were 1.56 times more likely to encounter motor vehicle collisions (95% CI, 1.05–2.32; p=0.027) than were controls (after adjustment; Table 2). No differences were observed in the incidence of motor vehicle collisions between groups with respect to history of motor vehicle collisions (adjusted HR 1.41 [95% CI, 0.94–2.10]), DUI (adjusted HR 0.61 [95% CI, 0.33–1.13]), antidepressant use (adjusted HR 1.70 [95% CI, 0.95–3.05]), or BZD (Z-drug) use (adjusted HR 1.25 [95% CI, 0.82–1.91]).
Table 2
Independent predictors of motor vehicle collisions among opiate users receiving methadone maintenance treatment (MMT).
| Variables | Crude hazard ratio (95% CI) | p | Adjusted hazard ratio (95% CI) | p | ||
|---|---|---|---|---|---|---|
| Education status | ||||||
| Elementary school | 1.00 | - | 1.00 | - | ||
| High school | 0.90 (0.50, 1.64) | 0.727 | 1.06 (0.53, 2.12) | 0.875 | ||
| College or more | 0.83 (0.26, 2.60) | 0.743 | 1.05 (0.28, 3.95) | 0.942 | ||
| Income level (New Taiwan $) | ||||||
| ≦15,000 | 1.27 (0.87, 1.86) | 0.220 | 1.14 (0.77, 1.67) | 0.516 | ||
| Urbanity | ||||||
| Urban | 1.00 | - | 1.00 | - | ||
| Suburban | 0.62 (0.15, 2.50) | 0.500 | 0.76 (0.19, 3.10) | 0.700 | ||
| Rural | 1.68 (1.14, 2.46) | 0.009 | 1.56 (1.05, 2.32) | 0.027 | ||
| Past history of | ||||||
| Motor vehicle collision (vs. no) | 1.70 (1.17, 2.48) | 0.006 | 1.41 (0.94, 2.10) | 0.097 | ||
| Driving under the influence (vs. no) | 2.26 (1.26, 4.01) | 0.006 | 0.61 (0.33, 1.13) | 0.116 | ||
| Antidepressant use (vs. no) | 2.25 (1.28, 3.93) | 0.005 | 1.70 (0.95, 3.05) | 0.076 | ||
| Benzodiazepine (Z-drug) use (vs. no) | 1.62 (1.09, 2.42) | 0.018 | 1.25 (0.82, 1.91) | 0.296 | ||
| Occurrence of motor vehicle collision | ||||||
| MMT (vs. non-MMT) | 3.00 (2.05, 4.38) | <0.001 | 2.75 (1.87, 4.04) | <0.001 | ||
Discussion
From 2009 to 2016, the crude incidence rates (CIRs) of motor vehicle collisions were the lowest in the general adult population, followed by those in adult opiate users, and the highest in adults receiving MMT. In the 7-year cohort study with frequency-matched controls, the motor vehicle collision incidence rate among opiate users was significantly higher in those receiving MMT than in those not receiving MMT. This rate drastically increased in opiate users receiving MMT during the first 90 days of follow-up. Rural area residents had increased motor vehicle collision risk. Although the occurrences of motor vehicle collisions in drivers under the influence of current opiate use, current opiate use during opiate withdrawal, BZD, and alcohol are higher than those receiving MMT, these factors (such as the history of BZD, antidepressants, and alcohol exposed) were nonsignificantly increased risk of motor vehicle collisions in opiate users receiving MMT.
In the preliminary analysis based on the nationwide CIRs of motor vehicle collisions, the CIRs in the general and opiate-using adult populations slowly increased toward a peak, followed by a slight decline. By contrast, the CIR in adults receiving MMT remained high, without such fluctuation. The risk of motor vehicle collisions was 1.45–1.62 times higher in adult opiate users and 1.66–2.34 times higher in adults receiving MMT than in the general adult population. Thus, adults receiving MMT had a consistently higher rate of motor vehicle collisions than did the general adult population. These findings corroborate those of three observational studies (Bramness et al., 2012; Corsenac et al., 2012; Leveille et al., 1994). These results do not eliminate the effects of interfering factors such as opiate use because most of the participants used opiates before receiving MMT. Furthermore, we included a retrospective cohort of opiate users receiving and not receiving MMT to eliminate such effects.
In this cohort study, among 3036 opiate users, those receiving MMT had a significantly higher motor vehicle collision risk than did those without such treatment. The percentage of opiate users with a motor vehicle collision event was approximately three times higher in the participants receiving MMT than in those not receiving MMT (6.5% vs. 2.2%). Compared with opiate users not receiving MMT, those receiving MMT had an increased risk of BZD (Z-drug) or antidepressant use, a result consistent with those of previous studies (Bramness et al., 2012; Corsenac et al., 2012; Bramness and Kornør, 2007). Univariate analysis showed that factors predictive of motor vehicle collisions in opiate users included a history of DUI, antidepressant use, BZD (Z-drug) use, and motor vehicle collisions. We found no significant difference in the incidence rate of motor vehicle collisions between the opiate user groups with respect to history of motor vehicle collisions, DUI, antidepressant use, and BZD (Z-drug) use. These findings suggest that these risk factors for motor vehicle collisions in the general population may nonsignificantly affect motor vehicle collisions in adult opiate users receiving MMT. Our results corroborate those of previous studies, demonstrating a positive correlation between motor vehicle collision risk and drivers’ exposure to methadone (Bramness et al., 2012; Corsenac et al., 2012; Leveille et al., 1994). In addition, our findings underscore the importance of considering motor vehicle collision risk during the first 90 days of methadone treatment. Authorities, physicians, and methadone users and their families should be educated regarding the elevated risk to prevent motor vehicle collisions. Further studies are needed to determine whether a policy forbidding driving during the first 90 days of MMT could effectively reduce motor vehicle collision risk.
The cause underlying the correlation between motor vehicle collisions and MMT use remains controversial. Studies have shown that methadone causes no or only slight impairment of psychomotor performance, particularly in chronic MMT (Specka et al., 2000; Brown et al., 2004; Rothenberg et al., 1977; Curran et al., 2001). By contrast, other studies have shown that methadone-maintained patients experience cognitive deficiencies (Specka et al., 2000; Staak et al., 1993; Dittert et al., 1999; Darke et al., 2000; Mintzer et al., 2005). Moreover, following 6 months of MMT compared to the first month, improved visuospatial construction and executive function, but no change in memory or attention performance, were found in a cross-sectional study (Soyka et al., 2010). Our results clearly demonstrate an elevated risk of motor vehicle collisions in drivers receiving MMT, particularly during the first 90 days of treatment. One possible explanation for this result is that MMT causes cognitive impairment only during the early stages of treatment.
Strengths and limitations
The major strength of our study is the use of a population-based sample of nationwide motor vehicle collision incidences and a case-comparison cohort for motor vehicle collisions. The findings may provide the basis for designing measures to prevent motor vehicle collisions during MTT, particularly in ethnic Chinese populations. Most observational studies showed different risks of motor vehicle collisions between two populations (the general population and the MMT population). We not only added the third population (the opiate-using population) in the preliminary study but also controlled for the potentially contributing factor of opioid use in the cohort study of opiate users receiving MMT and those not receiving. Furthermore, the data are not subject to reporting or recall bias because we used high-quality data from six administrative registries and the NHIRD. Nevertheless, we acknowledge several limitations. First, the administrative data was the lack of information on road exposure (driven hours or distances in a given period) because unobservable differences between the road exposure may confound the relationship of interest. Motor vehicle collisions in the study were assessed using the police registry. Hence, unreported or minor motor vehicle collisions may not be included in our analysis. Second, the number of opiate users and duration of opiate use may be underestimated. Opiate use is often underreported because it is illegal in Taiwan. Moreover, opioid doses were recognized much higher risks among MMT users than among non-MMT opioid users; hence, opiate dose was uncaptured because it was unavailable in our database. The data about enrollment in a nongovernmental organization institution for rehabilitation and severity of opiate use were lacking. Third, data from drivers’ licenses were lacking in our registry. Although motor vehicle collision risk may be underestimated in the study, we excluded participants aged <20 years to diminish underestimation. Fourth, the degree of exposure to unfavorable road conditions and information regarding unsafe road infrastructure, inadequate traffic laws, car speed, driver fatigue, talking on cell phones, and unsafe vehicles was unavailable in the present study (World Health Organization, 2018; Chang et al., 2013; Engeland et al., 2007; World Health Organization, 2004). Finally, the NHIRD only provides information regarding the dispensing of prescribed medications. Because nonadherence is considered a potential confounder, caution should be exercised when comparing our findings with the results reported by other groups in which data are collected from clinical settings (Chang et al., 2013; Engeland et al., 2007; World Health Organization, 2004; Babst et al., 1973; Blomberg and Preusser, 1974; Maddux et al., 1977; Gibson et al., 2009; Edwards and Quartaro, 1978).
In line with previous findings, we provided compelling evidence that opiate users on MTT have a significantly increased motor vehicle collision risk. Individuals receiving MMT should be informed of this risk, so that they can take appropriate measures to prevent motor vehicle collisions, particularly during the first 90 days of MMT and if living in rural areas.
Data availability
Data are available from the National Health Insurance Research Database (NHIRD) published by Taiwan National Health Insurance (NHI) Bureau. Due to legal restrictions imposed by the government of Taiwan in relation to the "Personal Information Protection Act", data cannot be made publicly available. Requests for data can be sent as a formal proposal to the NHIRD (http://nhird.nhri.org.tw).
References
-
Curbing prescription opioid dependency: an epidemic of overdoses and deaths from opioids is fuelled by increased prescribing and sales in North AmericaBulletin of the World Health Organization 95:318–319.https://doi.org/10.2471/BLT.17.020517
-
Sustained attention in methadone patientsInternational Journal of the Addictions 17:1313–1327.https://doi.org/10.3109/10826088209064064
-
Digit-symbol performance in methadone-treated ex-heroin addictsAmerican Journal of Psychiatry 133:1337–1340.https://doi.org/10.1176/ajp.133.11.1337
-
Driving records of methadone maintenance patients in New York stateJournal of Drug Issues 3:285–292.https://doi.org/10.1177/002204267300300401
-
Influence of peak and trough levels of opioid maintenance therapy on driving aptitudeEuropean Addiction Research 13:127–135.https://doi.org/10.1159/000101548
-
Narcotic use and driving behaviorAccident Analysis & Prevention 6:23–32.https://doi.org/10.1016/0001-4575(74)90013-X
-
Benzodiazepine prescription for patients in opioid maintenance treatment in NorwayDrug and Alcohol Dependence 90:203–209.https://doi.org/10.1016/j.drugalcdep.2007.03.008
-
Methadone: applied pharmacology and use as adjunctive treatment in chronic painPostgraduate Medical Journal 80:654–659.https://doi.org/10.1136/pgmj.2004.022988
-
Psychotropic drugs and risk of motor vehicle accidents: a population-based case-control studyBritish Journal of Clinical Pharmacology 75:1125–1133.https://doi.org/10.1111/j.1365-2125.2012.04410.x
-
BookMortality Amongst Illicit Drug Users: Epidemiology, Causes and InterventionCambridge: Cambridge University Press.https://doi.org/10.1017/CBO9780511543692
-
BookRegulations for the Management of Opioid DependenceTaipei: Department of Health, Executive Yuan of Taiwan.
-
Reaction-times of methadone treated ex-heroin addictsPsychopharmacologia 16:337–344.https://doi.org/10.1007/BF00404740
-
Physiological and psychological effects of methadone in manArchives of General Psychiatry 32:237.https://doi.org/10.1001/archpsyc.1975.01760200101010
-
Trends in opiate-related deaths in the united kingdom and Australia, 1985-1995Drug and Alcohol Dependence 57:247–254.https://doi.org/10.1016/S0376-8716(99)00057-5
-
Methadone maintenance: an assessment of potential fluctuations in behavior between dosesInternational Journal of the Addictions 13:1061–1068.https://doi.org/10.3109/10826087809039326
-
Driving records before and during methadone maintenanceThe American Journal of Drug and Alcohol Abuse 4:91–100.https://doi.org/10.3109/00952997709002750
-
Opioid abuse and cognitive performanceDrug and Alcohol Dependence 78:225–230.https://doi.org/10.1016/j.drugalcdep.2004.10.008
-
Cognitive impairment in methadone maintenance patientsDrug and Alcohol Dependence 67:41–51.https://doi.org/10.1016/S0376-8716(02)00013-3
-
BookMethadone maintenance and tracking performanceIn: Kaye S, Meier G. W, editors. Alcohol, Drugs and Traffic Safety. Washington, DC: U.S. Department of Transport. pp. 995–1004.
-
BookMethadone maintenance treatment and aspects of skilled performanceIn: Kaye S, Meier G. W, editors. Alcohol, Drugs and Traffic Safety. Washington, DC: U.S. Department of Transport. pp. 1145–1157.
-
Performance differences between addicts and non-addictsPsychopharmacology 52:299–306.https://doi.org/10.1007/BF00426715
-
Impaired performance in a test of decision-making by opiate-dependent tobacco smokersDrug and Alcohol Dependence 73:79–86.https://doi.org/10.1016/j.drugalcdep.2003.10.003
-
Maintenance therapy with synthetic opioids and driving aptitudeEuropean Addiction Research 10:80–87.https://doi.org/10.1159/000076118
-
Cognitive functioning during methadone and buprenorphine treatment: results of a randomized clinical trialJournal of clinical psychopharmacology 28:699–703.https://doi.org/10.1097/JCP.0b013e31818a6d38
-
Cognitive function in short- and long-term substitution treatment: are there differences?The World Journal of Biological Psychiatry 11:400–408.https://doi.org/10.3109/15622970902995604
-
Cognitive-motor performance of methadone-maintained patientsEuropean Addiction Research 6:8–19.https://doi.org/10.1159/000019004
-
[Empirical studies of automobile driving fitness of patients treated with methadone-substitution]Blutalkohol 30:321–333.
-
BookMethadone Maintenance Treatment GuidelinesTaipei: Taiwan Centers for Disease Control.
-
Neuropsychological functioning in methadone maintenance patients versus abstinent heroin abusersDrug and Alcohol Dependence 78:283–288.https://doi.org/10.1016/j.drugalcdep.2004.11.006
-
National Health Insurance database in Taiwan: A resource or obstacle for health research?European journal of internal medicine 31:e9–e10.https://doi.org/10.1016/j.ejim.2016.03.022
-
A review of the effects of opioids on psychomotor and cognitive functioning in humansExperimental and Clinical Psychopharmacology 3:432–466.https://doi.org/10.1037/1064-1297.3.4.432
Article and author information
Author details
Funding
Taiwan Food and Drug Administration (MOHW106-FDA-D-114-000671)
- Ya-Hui Yang
Taiwan Food and Drug Administration (MOHW107-FDA-D-114-000636)
- Ya-Hui Yang
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Acknowledgements
We would like to thank Miss Mei-Hsin Ho for her assistance and reference management. The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. Some of the data used in the present study were sourced from the Health and Welfare Data Science Center, Ministry of Health and Welfare (registered nos.: H106038 and H107088).
Ethics
Human subjects: The study was approved by the Institutional Review Boards (TSMH IRB No.: 17-010-B1 and 18-049-B); the need for written informed consent was waived because we used deidentified information from the databases.
Copyright
© 2021, Yang et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,189
- views
-
- 132
- downloads
-
- 2
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Risk of motor vehicle collisions after methadone use
eLife 10:e63954.
https://doi.org/10.7554/eLife.63954
Further reading
-
- Medicine
Background:
Clonal hematopoiesis of indeterminate potential (CHIP) was initially linked to a twofold increase in atherothrombotic events. However, recent investigations have revealed a more nuanced picture, suggesting that CHIP may confer only a modest rise in myocardial infarction (MI) risk. This observed lower risk might be influenced by yet unidentified factors that modulate the pathological effects of CHIP. Mosaic loss of the Y chromosome (mLOY), a common marker of clonal hematopoiesis in men, has emerged as a potential candidate for modulating cardiovascular risk associated with CHIP. In this study, we aimed to ascertain the risk linked to each somatic mutation or mLOY and explore whether mLOY could exert an influence on the cardiovascular risk associated with CHIP.
Methods:
We conducted an examination for the presence of CHIP and mLOY using targeted high-throughput sequencing and digital PCR in a cohort of 446 individuals. Among them, 149 patients from the CHAth study had experienced a first MI at the time of inclusion (MI(+) subjects), while 297 individuals from the Three-City cohort had no history of cardiovascular events (CVE) at the time of inclusion (MI(-) subjects). All subjects underwent thorough cardiovascular phenotyping, including a direct assessment of atherosclerotic burden. Our investigation aimed to determine whether mLOY could modulate inflammation, atherosclerosis burden, and atherothrombotic risk associated with CHIP.
Results:
CHIP and mLOY were detected with a substantial prevalence (45.1% and 37.7%, respectively), and their occurrence was similar between MI(+) and MI(-) subjects. Notably, nearly 40% of CHIP(+) male subjects also exhibited mLOY. Interestingly, neither CHIP nor mLOY independently resulted in significant increases in plasma hs-CRP levels, atherosclerotic burden, or MI incidence. Moreover, mLOY did not amplify or diminish inflammation, atherosclerosis, or MI incidence among CHIP(+) male subjects. Conversely, in MI(-) male subjects, CHIP heightened the risk of MI over a 5 y period, particularly in those lacking mLOY.
Conclusions:
Our study highlights the high prevalence of CHIP and mLOY in elderly individuals. Importantly, our results demonstrate that neither CHIP nor mLOY in isolation substantially contributes to inflammation, atherosclerosis, or MI incidence. Furthermore, we find that mLOY does not exert a significant influence on the modulation of inflammation, atherosclerosis burden, or atherothrombotic risk associated with CHIP. However, CHIP may accelerate the occurrence of MI, especially when unaccompanied by mLOY. These findings underscore the complexity of the interplay between CHIP, mLOY, and cardiovascular risk, suggesting that large-scale studies with thousands more patients may be necessary to elucidate subtle correlations.
Funding:
This study was supported by the Fondation Cœur & Recherche (the Société Française de Cardiologie), the Fédération Française de Cardiologie, ERA-CVD (« CHEMICAL » consortium, JTC 2019) and the Fondation Université de Bordeaux. The laboratory of Hematology of the University Hospital of Bordeaux benefitted of a convention with the Nouvelle Aquitaine Region (2018-1R30113-8473520) for the acquisition of the Nextseq 550Dx sequencer used in this study.
Clinical trial number:
-
- Biochemistry and Chemical Biology
- Medicine
HER2 overexpression significantly contributes to the aggressive nature and recurrent patterns observed in various solid tumors, notably gastric cancers. Trastuzumab, HER2-targeting monoclonal antibody drug, has shown considerable clinical success; however, readily emerging drug resistance emphasizes the pressing need for improved interventions in HER2-overexpressing cancers. To address this, we proposed targeting the protein-protein interaction (PPI) between ELF3 and MED23 as an alternative therapeutic approach to trastuzumab. In this study, we synthesized a total of 26 compounds consisting of 10 chalcones, 7 pyrazoline acetyl, and 9 pyrazoline propionyl derivatives, and evaluated their biological activity as potential ELF3-MED23 PPI inhibitors. Upon systematic analysis, candidate compound 10 was selected due to its potency in downregulating reporter gene activity of ERBB2 promoter confirmed by SEAP activity and its effect on HER2 protein and mRNA levels. Compound 10 effectively disrupted the binding interface between the ELF3 TAD domain and the 391–582 amino acid region of MED23, resulting in successful inhibition of the ELF3-MED23 PPI. This intervention led to a substantial reduction in HER2 levels and its downstream signals in the HER2-positive gastric cancer cell line. Subsequently, compound 10 induced significant apoptosis and anti-proliferative effects, demonstrating superior in vitro and in vivo anticancer activity overall. We found that the anticancer activity of compound 10 was not only restricted to trastuzumab-sensitive cases, but was also valid for trastuzumab-refractory clones. This suggests its potential as a viable therapeutic option for trastuzumab-resistant gastric cancers. In summary, compound 10 could be a novel alternative therapeutic strategy for HER2-overexpressing cancers, overcoming the limitations of trastuzumab.
